Clinical trial · Interventional
Study of the Expression of Met Receptor Fragments in Non Small Cell Lung Cancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Our project, established through collaboration between clinicians (Oscar Lambret Center-University Hospital) and scientists (IBL), aims to evaluate the expression of Met fragments in the lung cancer (LC). Unlike previous studies on Met by sequencing, in situ hybridization or immunohistochemistry, the investigators propose a protein analysis by Western blot of tumor samples and healthy tissue. This approach will evaluate the expression of full-length receptor, the potential presence of intracellular fragments, and their phosphorylation status.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Met analysis on tissue and blood | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Met analysis
- description
- Met analysis on tissue and blood Western Blot Immunohistochemistry ELISA test
- interventionNames
- Other: Met analysis on tissue and blood
Primary outcomes (1)
- measure
- Expression and localization of Met C-terminal active fragments in NSCLC
- timeFrame
- baseline
- description
- Western Blot and immunohistochemistry
Secondary outcomes (3)
- measure
- Evaluation of the activation of Met receptor
- timeFrame
- baseline
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with non small cell lung cancer (NSCLC) * Patients candidate for bronchial biopsies at the Oscar Lambret Center (metastatic stage) or candidate for thoracic surgery at University Hospital of Lille (localized stage) * Treatment naive patient for metastatic NSCLC * Patients with or without neoadjuvant therapy for localized NSCLC * Male or female patients aged ≥ 18 years * Patient registered with the social security system * Having signed a written Informed Consent Exclusion Criteria: * Malignant tumors which are not carcinoma * Small-cell malignant tumors * Secondary bronchial lesions * Revision surgery * Pregnant or breastfeeding women * Patient under guardianship or tutorship * Previous cancer
References
Publications (0)
Data not yet available